FFA
LRMR icon

Fi3 Financial Advisors’s Larimar Therapeutics LRMR Stock Holding History

Fi3 Financial Advisors’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$133K Buy
29,493
+171
+0.6% +$683 0.04% 215
2025
Q4 		$112K Buy
29,322
+82
+0.3% +$319 0.03% 190
2025
Q3 		$94.4K Buy
29,240
+5,068
+21% +$19K 0.03% 158
2025
Q2 		$69.9K Buy
24,172
+202
+0.8% +$468 0.03% 165
2025
Q1 		$51.5K Buy
23,970
+172
+0.7% +$544 0.02% 134
2024
Q4 		$92.1K Buy
23,798
+3,411
+17% +$22.5K 0.03% 121
2024
Q3 		$134K Hold
20,387
– – 0.05% 111
2024
Q2 		$148K Sell
20,387
-5,061
-20% -$38.8K 0.07% 83
2024
Q1 		$198K Hold
25,448
– – 0.09% 84
2023
Q4 		$116K Sell
25,448
-123
-0.5% -$415 0.06% 73
2023
Q3 		$101K Buy
25,571
+23
+0.1% +$87 0.05% 71
2023
Q2 		$80K Hold
25,548
– – 0.04% 69
2023
Q1 		$116K Hold
25,548
– – 0.06% 76
2022
Q4 		$106K Sell
25,548
-74,022
-74% -$253K 0.06% 70
2022
Q3 		$319K Sell
99,570
-22,248
-18% -$55.7K 0.29% 32
2022
Q2 		$239K Hold
121,818
– – 0.2% 43
2022
Q1 		$493K Hold
121,818
– – 0.38% 24
2021
Q4 		$1.31M Hold
121,818
– – 0.86% 19
2021
Q3 		$1.41M Hold
121,818
– – 0.93% 17
2021
Q2 		$1.22M Buy
121,818
+100,570
+473% +$1.14M 0.84% 18
2021
Q1 		$310K Buy
+21,248
New +$386K 0.27% 34

Other funds holding LRMR

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Fi3 Financial Advisors's LRMR Position: Q1 2026 in Review

Fi3 Financial Advisors increased its Larimar Therapeutics (LRMR) stake by 0.58% in Q1 2026, buying an estimated $683 and bringing the position to 29,493 shares worth $133K. The position accounts for 0.04% of the portfolio, ranked #215.

Fi3 Financial Advisors first reported a position in LRMR in Q1 2021 and has held it in 21 quarters since. The position peaked at $1.41M in Q3 2021. 162 funds tracked by Wall St. Rank hold LRMR as of Q1 2026.

  • Fi3 Financial Advisors held 29,493 shares of Larimar Therapeutics worth $133K as of Q1 2026.
  • Fi3 Financial Advisors bought 171 Larimar Therapeutics shares in Q1 2026, an estimated $683.
  • Larimar Therapeutics made up 0.04% of Fi3 Financial Advisors's portfolio in Q1 2026, its #215 holding.
  • Fi3 Financial Advisors first reported a position in Larimar Therapeutics in Q1 2021 and has held it in 21 quarters since.
  • Fi3 Financial Advisors's Larimar Therapeutics position peaked at $1.41M in Q3 2021.
  • 162 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q1 2026.

Based on Fi3 Financial Advisors's 13F filing for Q1 2026, filed 7 May 2026.